Key Highlights

  • Aeternum Health finalized a reverse merger on June 30, 2026, acquiring 51% control with 49 million common shares issued.
  • The company secured at least $1.5 million in assets, including critical mineral sourcing and anti‑aging peptide IP.
  • Authorized shares remain at a level sufficient for future financing activities.
  • Leadership transitioned to Paul Mann, replacing former CEO Jeff Kim post‑merger.

Merger Completion Marks Strategic Shift

On June 30, 2026, Aeternum Health, Inc. Closed a reverse merger that redirected its focus from transportation electrification toward the extraction of strategic minerals and the development of longevity‑related health solutions. The transaction placed Paul Mann’s Aeternum Health LLC in a controlling position within the rebranded enterprise, reflecting a calculated move into two high‑growth arenas that are currently drawing significant investor interest.

Asset Transfer and Financial Terms

The merger agreement obliged Aeternum Health to deliver assets valued at a minimum of $1,500,000. These assets comprise capabilities for sourcing critical minerals essential to defense and renewable‑energy supply chains, together with proprietary intellectual property tied to a novel anti‑aging peptide. An additional cash component of at least $300,000 accompanied the asset transfer, furnishing the combined company with the initial capital needed to pursue its dual‑sector strategy.

Ownership and Share Restructuring

In exchange for the transferred assets, Paul Mann received 49,000,000 shares of common stock, equating to a 51% ownership stake in the surviving corporation. Moreover, the company issued 2,000,000 Series B preferred shares, each bearing voting rights comparable to forty common shares. While the firm’s charter already accommodates a sizable authorized share count, no specific amendment to that figure is disclosed in the public filing.

This structure provides flexibility for subsequent equity issuances should the company elect to raise additional capital or acquire complementary businesses.

Leadership and Rebranding

Following the consummation of the merger, Jeff Kim, formerly chief executive of Shorepower Technologies, stepped down, and Paul Mann assumed the roles of president and sole director. The rebranded entity now operates under the name Aeternum Health, Inc. And trades on the market using the ticker symbol AETN, a change that was officially recorded in early March 2026. Mann’s background in both longevity research and mineral sourcing is expected to guide the firm’s strategic direction.

Sector Focus and Market Risks

Aeternum Health’s emerging business model rests on two pillars. The first targets the procurement and processing of critical minerals, a segment bolstered by U.S. Government initiatives aimed at reducing dependence on foreign sources. The second concentrates on longevity‑focused therapeutics, an area marked by rapid scientific advances but also by stringent regulatory pathways and intense competition.

Risks inherent to the mining side include geopolitical volatility in mineral‑rich regions, fluctuating commodity prices, and potential trade restrictions. On the health‑care front, challenges encompass lengthy clinical development timelines, uncertain reimbursement landscapes, and the need for robust efficacy data.

Forward‑Looking Statements and Caution

The company’s public disclosures contain forward‑looking language regarding its capacity to commercialize the newly acquired assets and to navigate macro‑economic headwinds. Investors should consider that outcomes may differ materially from current expectations due to factors such as supply‑chain interruptions, regulatory shifts, and market turbulence.

Trading and Investor Outlook

Since the merger, Aeternum Health’s shares have reflected heightened market interest in firms that blend resource extraction with biotech innovation. While the infusion of assets and the restructured equity base provide a catalyst for near‑term activity, the firm’s limited operating history and the nascent stage of its product pipeline introduce considerable execution risk. Analysts will be watching closely for any secured contracts in the critical minerals arena and for progress milestones in the peptide‑based longevity program.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.